Your browser is no longer supported. Please, upgrade your browser.
PSTI Pluristem Therapeutics Inc. daily Stock Chart
Pluristem Therapeutics Inc.
Index- P/E- EPS (ttm)-0.25 Insider Own10.70% Shs Outstand115.10M Perf Week2.00%
Market Cap117.40M Forward P/E- EPS next Y-0.14 Insider Trans0.00% Shs Float106.53M Perf Month-8.11%
Income-28.00M PEG- EPS next Q-0.08 Inst Own5.40% Short Float2.47% Perf Quarter-12.82%
Sales0.05M P/S2174.11 EPS this Y22.40% Inst Trans7.54% Short Ratio9.86 Perf Half Y-18.40%
Book/sh0.13 P/B7.85 EPS next Y53.30% ROA-81.60% Target Price3.67 Perf Year-25.00%
Cash/sh0.13 P/C7.99 EPS next 5Y- ROE-113.70% 52W Range0.66 - 1.60 Perf YTD29.43%
Dividend- P/FCF- EPS past 5Y8.30% ROI- 52W High-36.25% Beta1.38
Dividend %- Quick Ratio2.50 Sales past 5Y- Gross Margin- 52W Low54.45% ATR0.05
Employees172 Current Ratio2.50 Sales Q/Q0.00% Oper. Margin- RSI (14)45.52 Volatility4.78% 4.17%
OptionableYes Debt/Eq0.00 EPS Q/Q4.20% Profit Margin- Rel Volume0.57 Prev Close1.00
ShortableYes LT Debt/Eq0.00 EarningsFeb 05 Payout- Avg Volume266.77K Price1.02
Recom- SMA20-6.49% SMA501.76% SMA200-14.96% Volume152,762 Change1.49%
Feb-13-17Downgrade Maxim Group Buy → Hold
Jul-19-16Resumed H.C. Wainwright Buy $3.50
Dec-22-15Reiterated Maxim Group Buy $8 → $3
Feb-03-15Reiterated Needham Buy $5 → $4
Sep-22-14Resumed Oppenheimer Outperform
Sep-08-14Initiated H.C. Wainwright Buy $4
Jan-21-14Reiterated MLV & Co Buy $4.50 → $6
Sep-16-13Upgrade Maxim Group Hold → Buy $8
Jun-04-13Downgrade Maxim Group Buy → Hold
May-31-13Initiated MLV & Co Buy $4.50
Jul-25-12Initiated Maxim Group Buy $8
Jul-24-12Downgrade WBB Securities Speculative Buy → Hold $4 → $3.75
May-22-12Initiated Needham Buy $5
Dec-09-11Initiated Global Hunter Securities Speculative Buy $5
Jun-17-11Initiated Dawson James Buy $5
May-17-11Initiated Oppenheimer Outperform $5
Mar-01-11Initiated WBB Securities Speculative Buy $4
Jan-10-11Initiated National Securities Buy
Feb-14-19 06:06AM  Pluristem Therapeutics Sees Hammer Chart Pattern: Time to Buy? Zacks
Feb-11-19 10:19AM  RESTORE Consortium, of which Pluristem is a member, Nominated to Be One of Two Finalists Competing for a Potential Award for Development of Advanced Therapeutics GlobeNewswire
Feb-07-19 03:31PM  Pluristem: Fiscal 2Q Earnings Snapshot Associated Press
Jan-28-19 11:41AM  Read This Before Buying Pluristem Therapeutics Inc. (NASDAQ:PSTI) Shares Simply Wall St.
Jan-22-19 07:00AM  Pluristem to Collaborate with Israeli Ministry of Defense in the Treatment of Burn Injuries GlobeNewswire
Jan-09-19 08:00AM  Pluristem Therapeutics Reports Successful Case Study in Treatment of Buergers Disease Patient GlobeNewswire +5.66%
Jan-03-19 08:30AM  Pluristem Concludes Positive Meeting with FDA on Development Plan for Acute Radiation Syndrome GlobeNewswire +7.32%
Dec-17-18 08:40AM  Pluristem Therapeutics Recaps Key Opinion Leader Meeting on Peripheral Artery Disease (PAD) GlobeNewswire
Dec-13-18 11:59AM  Reminder- Pluristem Therapeutics to Host Key Opinion Leader Meeting on Peripheral Artery Disease Tomorrow GlobeNewswire
Dec-04-18 07:00AM  Pluristem Therapeutics Enters into Cell Thawing Device License Agreement with Chart Industries, Inc. GlobeNewswire
Dec-03-18 07:00AM  Pluristem Presents Data from First Cohort in Ongoing Phase I Hematological Study at the American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Nov-30-18 05:32AM  Pluristem Therapeutics Sees Hammer Chart Pattern: Time to Buy? Zacks
Nov-29-18 07:30AM  The Real Impact of PAD - Pluristem Therapeutics to Host Key Opinion Leader Meeting on Peripheral Artery Disease GlobeNewswire
Nov-28-18 08:00AM  Pluristem to Present First Cohort Data from PLX-R18 Hematological Study at American Society of Hematologys (ASH) Annual Meeting GlobeNewswire
Nov-20-18 11:20AM  What Kind Of Investor Owns Most Of Pluristem Therapeutics Inc (NASDAQ:PSTI)? Simply Wall St.
Nov-19-18 08:15AM  Report: Exploring Fundamental Drivers Behind Pluristem Therapeutics, RXi Pharmaceuticals, Saga Communications, Global Self Storage, Sequential Brands Group, and Finjan New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-12-18 07:30AM  New Findings from Pluristems Phase II IC study: PLX-PAD Cells Significantly Improves Blood Glucose Control (HbA1c) and Reduce Chronic Inflammation GlobeNewswire
Nov-08-18 10:42AM  Pluristem: Fiscal 1Q Earnings Snapshot Associated Press
07:00AM  Pluristem Therapeutics Reports Fiscal 2019 First Quarter Results and Provides Corporate Update GlobeNewswire
Oct-18-18 06:30AM  Pluristem Therapeutics Selected to Present Data from Phase II IC Study at the American Heart Association Scientific Sessions GlobeNewswire
Oct-16-18 07:00AM  U.S. FDA Approves Cost Recovery for PLX-PAD under Expanded Access Program in the Treatment of Critical Limb Ischemia GlobeNewswire
Oct-10-18 07:00AM  Pluristem Therapeutics Announces Publication in JCSM of Two-Year Follow-Up Data from Phase I/II Study in Muscle Regeneration and European Clearance for Ongoing Phase III Study GlobeNewswire
Sep-27-18 07:00AM  Pluristem Reports Fiscal 2018 Fourth Quarter Results and Provides Corporate Update GlobeNewswire
Sep-20-18 12:10PM  What does Pluristem Therapeutics Incs (NASDAQ:PSTI) Balance Sheet Tell Us About Its Future? Simply Wall St.
Aug-08-18 07:00AM  Pluristem Initiates Two Pivotal Phase III Studies in Israel GlobeNewswire
Jul-31-18 03:16PM  Pluristem Therapeutics, Rexahn Pharma Are Biotech Winners, B Riley FBR Says In Bullish Initiation Benzinga
Jul-26-18 07:00AM  Pluristem Granted Key Patent in Japan for Treatment of GI Following Acute Radiation Exposure GlobeNewswire
Jul-19-18 07:05AM  Free Technical Reports on Portola Pharma and Three Additional Biotech Equities ACCESSWIRE
Jul-09-18 07:00AM  Pluristem Signs Collaboration Agreement With Thermo Fisher Scientific GlobeNewswire
Jun-25-18 07:26AM  Pluristem shares jump 2% on news of positive trial of treatment for radiation damage MarketWatch
07:00AM  Pluristem and Fukushima University Report Positive Data: PLX-R18 Increases Survival Rates and Mitigates Severe Intestinal Damage after Acute Radiation Exposure GlobeNewswire
Jun-19-18 07:00AM  U.S. Department of Defense to Study Pluristems PLX-R18 for the Treatment of Mustard Gas Injuries GlobeNewswire
Jun-14-18 07:00AM  Pluristem to Open Weekly Market Trading at TASE Following Positive Study Results GlobeNewswire -5.26%
Jun-13-18 08:12PM  Should You Be Content With Pluristem Therapeutics Incs (NASDAQ:PSTI) Earnings Growth? Simply Wall St.
Jun-12-18 09:23AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga -6.43%
06:38AM  Israel's Pluristem sees positive results from leg pain study Reuters
06:00AM  Pluristem Reports Positive Top-Line Results from Its Multinational Phase II Intermittent Claudication Study GlobeNewswire
Jun-05-18 09:48AM  Options Traders Expect Huge Moves in Pluristem Therapeutics (PSTI) Stock Zacks
Jun-04-18 06:00AM  Pluristem to Announce Top-Line Results of Its Multinational Phase II Intermittent Claudication Study on June 12, 2018 GlobeNewswire
May-16-18 04:43PM  Pluristem Therapeutics Inc (NASDAQ:PSTI): Are Analysts Optimistic? Simply Wall St.
May-10-18 08:01AM  Pluristem: Fiscal 3Q Earnings Snapshot Associated Press
07:00AM  Pluristem Reports Third Quarter Fiscal 2018 Corporate and Financial Highlights GlobeNewswire
Apr-30-18 02:46PM  FDA Clears New Drug Application For Pluristem's PLX-R18; What's Next? Benzinga +6.45%
08:41AM  Benzinga Pro's 6 Stocks To Watch Today Benzinga
07:00AM  U.S. FDA Clears Pluristems IND to Treat Victims Exposed to Acute Radiation GlobeNewswire
07:00AM  FDA clears Pluristem radiation treatment for emergency use Reuters
Apr-25-18 08:46AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:00AM  U.S. FDA Clears Pluristems Phase III Study in Treatment of Muscle Injury Following Hip Fracture Surgery GlobeNewswire
Apr-23-18 07:00AM  Pluristem and Indiana University to Initiate Joint Project Evaluating PLX-R18 in Acute Radiation Syndrome, Targeting Bridging Data for Pivotal Study GlobeNewswire
Mar-26-18 07:00AM  Roger Jeffs, Former Co-CEO of United Therapeutics, Joins Pluristem's Strategic Advisory Board GlobeNewswire
Feb-27-18 07:00AM  Pluristems PLX-R18 Improves Hematopoietic Transplantation as Reported in Scientific Journal Frontiers in Medicine GlobeNewswire +5.84%
Feb-15-18 08:47PM  What You Must Know About Pluristem Therapeutics Incs (NASDAQ:PSTI) Major Investors Simply Wall St.
Feb-07-18 07:44AM  Pluristem Issues Letter to Shareholders GlobeNewswire
Jan-31-18 02:12PM  N.Korea threats spur U.S. search for new radiation therapies Reuters
Jan-17-18 07:30AM  Wired News Pluristems PLX Cells Demonstrated Inhibition of Cancer Cell Growth in Peer-Reviewed Article ACCESSWIRE
Jan-12-18 07:00AM  Pluristems PLX Cells Significantly Inhibit Cancer Cell Growth in Newly Published Study GlobeNewswire +5.92%
Jan-09-18 07:00AM  FDA Clears Pluristems Expanded Access Program to Initiate Treatments of Critical Limb Ischemia Outside of Ongoing Phase III Study GlobeNewswire +8.84%
Dec-25-17 11:55AM  Does Pluristem Therapeutics Incs (NASDAQ:PSTI) Past Performance Indicate A Weaker Future? Simply Wall St.
Dec-12-17 07:30AM  Wired News VistaGen Receives US Patent on Methods for Producing Blood Cells, Platelets, and Bone Marrow Stem Cells ACCESSWIRE
05:30AM  Pluristem Granted Manufacturer Authorization and Good Manufacturing Practice (GMP) Certification by Israels Ministry of Health, Supporting Pivotal-Stage Studies GlobeNewswire
Dec-07-17 05:08AM  Pluristem to Present Data on PLX-R18 in Treatment of Acute Radiation Syndrome at American Society of Hematologys Annual Meeting GlobeNewswire
Nov-29-17 07:00AM  Peer-Reviewed Article Published on Pluristems PLX-PAD Cells Mechanism of Action to Restore Blood Flow in Ischemic Tissue GlobeNewswire
Nov-22-17 07:00AM  Pluristem Granted Key U.S. Patent for Skeletal Muscle Regeneration - a Meaningful Asset Ahead of Upcoming Phase III Femoral Neck Fracture Study GlobeNewswire
Nov-14-17 07:00AM  Pluristem Reports First Quarter Fiscal 2018 Corporate and Financial Highlights GlobeNewswire
Nov-13-17 06:05AM  Is It Time To Buy Pluristem Therapeutics Inc (PSTI)? Simply Wall St.
Nov-08-17 03:59PM  Pluristem reports 1Q loss Associated Press
Nov-06-17 07:00AM  Pluristem Enters into Agreement with Tel Aviv Sourasky Medical Center to Conduct Phase I/II Trial in Steroid-Refractory Chronic GvHD GlobeNewswire
Oct-30-17 02:45PM  Pluristem Announces Pricing of Public Offering of Common Stock on the Tel Aviv Stock Exchange GlobeNewswire -14.72%
Oct-29-17 05:49PM  Pluristem Proposes to Launch a Public Offering of Common Stock on the Tel Aviv Stock Exchange After Concluding an Israeli Institutional Investors Tender GlobeNewswire
Oct-26-17 07:00AM  Following Approval of Israels Ministry of Health, Pluristem Extends its Trial of PLX-R18 to Treat Insufficient Hematopoietic Recovery after Bone Marrow Transplant and Opens Clinical Centers in Israel GlobeNewswire
Oct-23-17 07:00AM  Pluristem Expands its Reach in the Treatment of Impaired Hematopoietic Systems with a European Patent Covering PLX-R18 in Chemotherapy, ARS, Genetic Disorders and Autoimmune Diseases GlobeNewswire
Oct-19-17 07:30AM  FDA Grants Pluristem Orphan Drug Designation for Its PLX-R18 Cell Therapy as Treatment for Acute Radiation Syndrome GlobeNewswire
Oct-16-17 07:00AM  New Published Data Highlights the Potential of Pluristem's PLX Cells in Improving Cardiac Function in Diabetes GlobeNewswire
Oct-12-17 08:00AM  Today's Research Reports on Trending Tickers: Athersys and Pluristem Therapeutics ACCESSWIRE
Oct-11-17 08:47AM  Pluristem Therapeutics Inc. (PSTI) Catches Eye: Stock Jumps 5.1% Zacks +15.24%
Oct-02-17 07:00AM  $7.9 Million Granted to nTRACK Collaborative Project Designed to Study Pluristems PLX-PAD Cells GlobeNewswire
Sep-29-17 07:00AM  Earnings Review and Free Research Report: Pluristem Announced Fiscal 2017 Results ACCESSWIRE
Sep-26-17 07:00AM  Pluristem Receives Positive Feedback from FDA and EMA as Company Prepares for Phase III Trial of PLX-PAD to Support Recovery from Hip Fracture GlobeNewswire
Sep-20-17 07:10AM  Corporate News Blog - Nabriva Therapeutics Declares Positive Top-line Results from Phase-3 Clinical Trial Evaluating Lefamulin for the Treatment of CABP ACCESSWIRE +6.85%
Sep-19-17 10:35AM  Pluristem's Ischemia Candidate Gets Fast Track Designation Zacks
Sep-18-17 10:30AM  Biotech Stocks Surging in September ACCESSWIRE +5.97%
10:15AM  Pluristem Wins Key FDA Approval 24/7 Wall St.
08:07AM  UPDATE: Pluristem stock jumps 21% premarket after FDA grants CLI treatment fast-track designation MarketWatch
07:00AM  U.S. FDA Grants Fast Track Designation to Pluristem's PLX-PAD for the Treatment of Critical Limb Ischemia (CLI) GlobeNewswire
Sep-13-17 07:00AM  Pluristem Strengthens Its Position in Asia, Awarded Two New Patents in Hong Kong for Critical Limb Ischemia and Muscle Regeneration GlobeNewswire +9.76%
Sep-11-17 08:17AM  Pluristem Reports Fourth Quarter and Fiscal 2017 Corporate and Financial Highlights GlobeNewswire +9.40%
06:51AM  Should You Buy Pluristem Therapeutics Inc (PSTI)? Simply Wall St.
Sep-05-17 07:00AM  $8.7 Million Awarded to Support Phase III Femoral Neck Fracture Trial by EU Horizon 2020 Program GlobeNewswire
Aug-17-17 08:00AM  Today's Research Reports on Stocks to Watch: Teva Pharmaceutical and Pluristem Therapeutics ACCESSWIRE
Aug-16-17 03:23PM  These Are the Hottest Stocks on the Planet Wednesday: URBN, TGT, PSTI, CSCO +5.31%
09:45AM  Biotech Movers: Disappointment for Bristol-Myers Kidney Combo Boosts Exelixis
07:30AM  U.S. Department of Defense to Conduct Studies of Pluristems PLX-R18 in a New ARS Project for Use Before Radiation Exposure GlobeNewswire
Aug-09-17 07:00AM  Israeli Government to Support Pluristems Marketing Activity in China Ministry of Economy Awards Company Smart Money Grant GlobeNewswire
Jul-27-17 08:00AM  Today's Research Reports on Trending Tickers: Biogen Inc. and Pluristem Therapeutics Inc. ACCESSWIRE
Jul-26-17 03:09PM  Pluristem stock rises 2.5% on mid-stage clinical trial results MarketWatch
01:00PM  New Data from ARS Study Shows Significant Hematological Deficiencies Even at Low Radiation Levels; PLX-R18 Supports Hematological Recovery GlobeNewswire
Jul-18-17 07:16AM  This new drug could help the U.S. survive a nuclear meltdown MarketWatch
Jul-10-17 07:00AM  Pluristem Advances its Multinational Phase III Critical Limb Ischemia Study, Targeting Initiation at 40 Active Sites by the End of 2017 GlobeNewswire
Jun-29-17 07:00AM  Pluristem to Present New Data from ARS study at Radiology Conference in U.S. GlobeNewswire
May-22-17 07:30AM  Pluristem Provides Shareholder Update on Corporate and Clinical Developments GlobeNewswire +8.46%
Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops PLacental eXpanded (PLX) cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies; a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermediate claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GERMAIN MARKDirectorMar 16Sale1.4811,64017,227513,944Mar 19 05:08 PM
GERMAIN MARKDirectorMar 15Sale1.4834,23350,665525,584Mar 19 05:08 PM
GERMAIN MARKDirectorMar 14Sale1.5023,81835,727559,817Mar 15 05:12 PM